Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
FULC
Stock Latest News
Company Announcements
Fulcrum Therapeutics Highlights Progress in Sickle Cell Treatment
23h ago
8K
FULC
Premium
Company Announcements
Fulcrum Therapeutics Reports Q2 2025 Financial Results
23d ago
FULC
Premium
Ratings
Promising Potential of Fulcrum Therapeutics’ Pociredir: A Buy Rating Backed by Positive Phase 1b Study Results
29d ago
FULC
Premium
Ratings
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment
1M ago
FULC
Premium
The Fly
H.C. Wainwright upgrades Fulcrum to Buy on sickle cell data
1M ago
FULC
Premium
The Fly
Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
1M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $15 from $12 at Oppenheimer
1M ago
FULC
Premium
Company Announcements
Fulcrum Therapeutics Announces Promising Phase 1b Trial Results
1M ago
8K
FULC
Premium
The Fly
Fulcrum Therapeutics’ pociredir shows efficacy in sickle cell disease
1M ago
FULC
Premium
The Fly
Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)
1M ago
FULC
Premium
The Fly
Fulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $6 from $2 at BofA
2M ago
FULC
Premium
Ratings
Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus
2M ago
FULC
Premium
Company Announcements
Fulcrum Therapeutics Elects New Directors at Annual Meeting
2M ago
8K
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler
3M ago
FULC
Premium
The Fly
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
3M ago
X
BAH
Premium
The Fly
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Leerink
3M ago
FULC
Premium
The Fly
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
4M ago
C
AA
Premium
The Fly
Cantor upgrades Fulcrum to Overweight on sickle cell opportunity
4M ago
FULC
Premium
The Fly
Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
4M ago
FULC
Premium
The Fly
Oppenheimer biotech analyst holds an analyst/industry conference call
4M ago
FULC
Premium
Ratings
Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
4M ago
FULC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
